Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25478930 | 0.89 | HTT (0.55) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL30083768 | 0.85 | MEN1 (0.47) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL25478938 | 0.85 | MEN1 (0.47) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL715061 | 0.81 | FGFR1 (0.50) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL31221221 | 0.81 | NR1H4 (0.50) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL27950708 | 0.76 | NR1H4 (0.45) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL8343144 | 0.76 | CYP17A1 (0.58) | NR1H4FGFR1SRCCYP17A1CDK2 | |
| SCHEMBL7605205 | 0.76 | EGLN1 (0.46) | NR1H4FGFR1SRCHTTCYP17A1 | |
| SCHEMBL18424880 | 0.74 | NR1H4 (0.35) | NR1H4FGFR1SRCHTTCYP17A1 | |
| Bromobenzene SCHEMBL28699914 | 0.72 | HTT (0.82) | FGFR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079763-A1 | TRIPHENYLPHOSPHINE OXIDE DERIVATIVE AND ELECTROPHOSPHORESCENT LUMINESCENT DEVICE | WUHAN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2018-03-22 | — | — | US | disclosed |
| US-9818952-B2 | Condensed cyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-11-14 | — | — | US | disclosed |
| US-20150108440-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079763-A1 | TRIPHENYLPHOSPHINE OXIDE DERIVATIVE AND ELECTROPHOSPHORESCENT LUMINESCENT DEVICE | SLC6A12, SLC35B2, NUDT1 | NR1H4 4200/4885FGFR1 4868/4885SRC 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.